A new look at the most successful prodrugs for active vitamin D (D hormone): Alfacalcidol and doxercalciferol

Molecules

Volumn 14, Issue 10, 2009, Pages 3869-3880

  Kubodera, Noboru ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Alfacalcidol; D hormone; Doxercalciferol; Practical syntheses; Prodrugs; Vitamin D

Indexed keywords

1 ALPHA HYDROXYERGOCALCIFEROL; 1 ALPHA-HYDROXYERGOCALCIFEROL; 1-HYDROXYCHOLECALCIFEROL; ALFACALCIDOL; ERGOCALCIFEROL; HYDROXYCOLECALCIFEROL; PRODRUG; VITAMIN; VITAMIN D;

BIOSYNTHESIS; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM; REVIEW; RICKETS; SECONDARY HYPERPARATHYROIDISM;

DRUG DESIGN; ERGOCALCIFEROLS; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; PRODRUGS; RICKETS; VITAMIN D; VITAMINS;

EID: 70350502279     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules14103869     Document Type: Review

References (36)

1. DeLuca, H.F. Historical overview. In Vitamin D; Feldman, D., Glorieux, F.H., Pike, J.W., Eds.; Academic Press: San Diego, CA, USA, 1997; pp. 3-11.
2. DeLuca, H.F. Historical perspective. In Vitamin D, 2nd ed.; Feldman, D., Pike, J.W., Glorieux, F.H., Eds.; Elsevier Academic Press: Burlington, MA, USA, 2005; pp. 3-12.
3. Laing, C.J.; Cooke, N.E. Vitamin D binding protein. In Vitamin D, 2nd ed.; Feldman, D., Pike, J.W., Glorieux, F.H., Eds.; Elsevier Academic Press: Burlington, MA, USA, 2005; pp. 117-134.
4. Horst, R.L.; Reinhardt, T.A.; Reddy, G.S. Vitamin D metabolism. In Vitamin D, 2nd ed.; Feldman, D., Pike, J.W., Glorieux, F.H., Eds.; Elsevier Academic Press: Burlington, MA, USA, 2005; pp. 15-36.
5. Pike, J.W.; Shevde, N.K. The vitamin D receptor. In Vitamin D, 2nd ed.; Feldman, D., Pike, J.W., Glorieux, F.H., Eds.; Elsevier Academic Press: Burlington, MA, USA, 2005; pp. 167-191.
6. Higuchi, Y.; Sato, K.; Nanjo, M.; Isogai, T.; Takeda, S.; Kumaki, K.; Nishii, Y. 1α- Hydroxycholecalciferol prevents osteoporosis induced by ovariectomy in the rats. Vitamins 1994, 68, 87-93.
7. Nishii, Y. Active vitamin D and its analogs as drugs for the treatment of osteoporosis: Advantages and problems. J. Bone Miner. Metab. 2002, 20, 57-65.
8. Shiraishi, A.; Higashi, S.; Ohkawa, H.; Kubodera, N.; Hirasawa, T.; Ezawa, I.; Ikeda, K.; Ogata, E. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif. Tissue Int. 1999, 65, 311-316.
9. Uchiyama, Y.; Higuchi, Y.; Takeda, S.; Masaki, T.; Shira-Ishi, A.; Sato, K.; Kubodera, N.; Ikeda, K.; Ogata. E. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002, 30,582-588.
10. Ikeda, K.; Ogata, E. The effect of vitamin D bon Osteoblasts and Osteoclasts. Curr Opin Orthop 1999, 10, 339-343.
11. 3 derivative, on calcium metabolism. Biochem. Biophy. Res. Commun. 1989, 163, 1444-1449.
12. Matsumoto, T.; Miki, T.; Hagino, H.; Sugimoto, T.; Okamoto, S.; Hirota, T.; Tanigawara, Y.; Hayashi, Y.; Fukunaga, M.; Shiraki, M.; Nakamura, T. A new vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: A randomized, double-blind, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab. 2005, 90, 5031-5036.
13. 3 analogs. Curr. Bioactive Compds. 2006, 2, 301-315.
14. Papapoulos, S.E. Bisphosphonates. Pharmacology and use in the treatment of osteoporosis. In Osteoporosis; Marcus, R., Feldman, D., Kelsey, J., Eds.; Academic Press: San Diego, CA, USA, 1996; pp. 1209-1234.
15. Nishii, Y.; Okano, T. History of the development of new vitamin D analogs: Studies on 22-oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy) calcitriol (ED-71). Steroids 2001, 66, 137-146.
16. 3 tritiated at 22 and 23 positions showing high specific radioactivity. Chem. Pharm. Bull. 2000, 48, 215-219.
17. 3. Calcif. Tissue Int. 1998, 63, 391-395.
18. 3 analogues. J. Syn. Org. Chem. Jpn. 2005, 63, 728-738, and internal information at Chugai Pharmaceutical Co., Ltd.
19. Kubodera, N.; Miyamoto, K.; Watanabe, H.; Kato, M.; Sasahara, K.; Ochi, K. An improved procedure for retro-cycloaddition of adducts from steroidal 5,7-dienes and 4-phenyl-1,2,4-triazoline-3,5-dione. J. Org. Chem. 1992, 57, 5019-5020.
20. Watanabe, H.; Kawanishi, T.; Miyamoto, K.; Kubodera, N.; Sasahara, K.; Ochi, K. Novel procedure for the preparation of 1α,3β-dihydroxy- 2β-tritiated steroidal compounds. Steroids 1992, 57, 444-446.
21. 3. Proc. Natl. Acad. Sci. USA 1981, 78, 4990-4994. (Pubitemid 12225607)
22. Bouillon, R.; Okamura, W.H.; Norman, A.W. Structure-function relationships in the vitamin D endocrine system. Endocrine Rev. 1995, 16, 200-257.
23. 3 analogs (deltanoids). In Vitamin D, 2nd ed.; Feldman, D., Pike, J.W., Glorieux, F.H., Eds.; Elsevier Academic Press: Burlington, MA, USA, 2005; pp. 1405-1422.
24. 3 in rat. Proc. Soc. Exp. Biol. Med. 1985, 178, 432-436.
25. Brown, A.J.; Dusso, A.S.; Slatopolsky, E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol. Dial. Transplant 2002, 17, 10-19.
26. Suda, T.; DeLuca, H.F.; Schnoes, H.K.; Blunt, J.W. The isolation and identification of 25-hydroxyergocalciferol. Biochemistry 1969, 8, 3515-3520.
27. 2. Arch. Biochem. Biophys. 1980, 202, 450-457.
28. 2. Biochemistry 1975, 14, 1250-1256.
29. 2. Biochemistry 1988, 27, 5785-5790.
30. 2 using the perfused rat kidney. Biochemistry 1979, 18, 1094-1101.
31. 2 produced in rat kidney. Biochemistry 1986, 25, 5328-5336.
32. Horst, R.L.; Reinhardt, T.A.; Ramberg, C.F.; Koszewski, N.J.; Napoli, J.L. 24-Hydroxylation of 1,25-dihydroxyergocalciferol. J. Biol. Chem. 1986, 261, 9250-9256.
33. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int. 1997, 51, 317-323.
34. Lm, H.-Y.; Schnoes, H.K.; DeLuca, H.F. Synthesis of 1α- hydroxyergocalciferol. Steroids 1977, 30, 671-677.
35. Shepherd, D.A.; Donia, R.A.; Campbell, J.A.; Johnson, B.A.; Holysz, R.P.; Slomp, G., Jr.; Stafford, J.E.; Pederson, R.L.; Ott, A.C. A synthesis of progesterone from ergosterol. J. Amer. Chem. Soc. 1955, 77, 1212-1215.
36. Kubodera, N. Pharmaceutical studies on vitamin D derivatives and practical synthesis of six commercially available vitamin D derivatives that contribute to current clinical practice. Heterocycles 2009, in press.